Genmab A (GMAB) Return on Capital Employed (2024 - 2026)

Genmab A (GMAB) posted Return on Capital Employed of 16.8% for Q1 2026, down 67.05% on a QoQ basis from 50.99% in Q3 2025.

Genmab A (GMAB) Return on Capital Employed (2024 - 2026) Analysis & Trends

Genmab A's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 16.8% for Q1 2026.

Quarterly Return on Capital Employed changed N/A year-over-year to 16.8% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.8% (changed N/A YoY) and the FY2025 annual result came in at 12.83%, changed N/A from the prior year.
Return on Capital Employed was 16.8% for Q1 2026 at Genmab A, down from 50.99% in the prior quarter.
Across five years, Return on Capital Employed topped out at 99.35% in Q4 2024 and bottomed at 16.8% in Q1 2026.
A 3-year average of 53.3% and a median of 48.52% in 2025 frame the typical range for Return on Capital Employed.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Oculis Holding AG	67,102.16 Bn	67,101.87 Bn	-	-31.80%
2	Nanobiotix	1,908.96 Bn	1,908.90 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	-107.40%
4	BeOne Medicines	474.03 Bn	469.24 Bn	1.35 Bn	10.46%
5	Vertex Pharmaceuticals	122.13 Bn	114.88 Bn	2.59 Bn	21.10%
6	Regeneron Pharmaceuticals	70.09 Bn	61.34 Bn	3.31 Bn	10.19%
7	Belite Bio	62.34 Bn	62.34 Bn	-	-
8	Argenx Se	55.96 Bn	50.77 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.53 Bn	34.52 Bn	959.66 Mn	20.34%
10	Genmab A	1.87 Bn	353.97 Mn	831.00 Mn	16.80%

Download Data